News

Fingolimod Reduces Alzheimer’s Disease Pathological Features in Mouse Model

Researchers tested the effects of fingolimod, an approved treatment for multiple sclerosis shown to have anti-inflammatory properties, in a mouse model of Alzheimer’s disease (AD). The drug reduced the density of pathological plaques and decreased the number of pro-inflammatory cells in in vivo disease models, suggesting a potential therapeutic role for Alzheimer’s.

Is Alzheimer’s a Medically Transmittable Disease? The Debate Continues

In September 2015, a study published in the journal Nature significantly stirred the scientific community and made people around the world understandably alarmed. The research suggested that Alzheimer’s disease might be transmittable through injections of the disease-driving protein amyloid-β. Researchers all over the world now race to further investigate these…

CONy16: New Alzheimer’s Phase 3 Tests of Amyloid-Beta Immunotherapies and an Exclusive Interview with Researcher

Two previously failed drug candidates, Eli Lilly’s Solanezumab and Roche’s Gantenerumab, are again under clinical study for Alzheimer’s disease. Both drugs are immunotherapies targeting amyloid-beta in the brain, a target that researchers — including Dr. Michael Geschwind, who spoke with Alzheimer’s News Today — think has the potential to revolutionize…